Anti-CEACAM5 ADC M9140 in Chinese Participants With Solid Tumors (PROCEADE-CRC-02)
The purpose of this study is to evaluate the safety and early clinical activity of M9140 in Chinese participants with locally advanced or metastatic colorectal cancer (CRC).
Solid Tumors|Colorectal Cancer
DRUG: M9140
Number of Participants With Dose Limiting Toxicities (DLTs), Up to 21 days (Each cycle is of 21 days)|Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Up to 8 months
Pharmacokinetic (PK) Plasma Concentrations of M9140, Cycle 1 Day 1 (C1D1) - Predose, 6, 24, 168, 336 hr (hour) post dose: predose C2D1; C3D1 - Predose, 6, 24, 336 hr postdose; C4D1 - predose every 2 cycles until treatment discontinuation (20 months). [Each cycle is of 21 days]|Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigators, Time from first study treatment throughout the study duration until progressive disease or death up to approximately 8 months|Duration of Response (DoR) According to RECIST v1.1 as Assessed by Investigator, Time from first study treatment throughout the study duration until progressive disease or death up to approximately 8 months|Progression-free Survival (PFS) According to RECIST v1.1, Time from first study treatment throughout the study duration until progressive disease or death up to approximately 8 months
The purpose of this study is to evaluate the safety and early clinical activity of M9140 in Chinese participants with locally advanced or metastatic colorectal cancer (CRC).